Elamipretide (SS-31): A Mitochondria-Targeted Peptide for Cellular Health and Disease Treatment
Explore the groundbreaking potential of this peptide in enhancing mitochondrial function and treating various health conditions.
Get a Quote & SampleProduct Core Value
Mitochondria-Targeted Peptide
Elamipretide, also known as SS-31 or MTP-131, is a revolutionary peptide that directly targets and improves mitochondrial function. By interacting with cardiolipin in the inner mitochondrial membrane, it enhances cellular energy production, reduces oxidative stress, and offers significant therapeutic potential for a range of diseases linked to mitochondrial dysfunction.
- The SS-31 mitochondria targeting peptide has shown promise in improving mitochondrial respiration and ATP production, crucial for cellular energy.
- Elamipretide's unique mechanism of action stabilizes cardiolipin, a key phospholipid in the inner mitochondrial membrane, thereby preserving mitochondrial integrity.
- This peptide acts as a potent inhibitor of reactive oxygen species (ROS) production, mitigating cellular damage caused by oxidative stress.
- Research into Elamipretide clinical trials suggests its efficacy in treating conditions such as dry AMD, mitochondrial myopathy, and Barth syndrome.
Benefits Provided by the Product
Enhanced Mitochondrial Function
Elamipretide’s ability to target mitochondria directly leads to improved cellular energy output, which is fundamental for overall health and combating fatigue associated with mitochondrial disorders.
Reduced Oxidative Stress
By neutralizing harmful reactive oxygen species (ROS), Elamipretide protects cells from damage, which is critical for preventing disease progression and promoting cellular longevity.
Therapeutic Potential in Rare Diseases
The ongoing study of Elamipretide for conditions like Barth syndrome highlights its significant therapeutic potential in addressing unmet medical needs in rare and debilitating diseases.
Key Applications
Mitochondrial Health
Elamipretide is a key molecule in research focused on enhancing overall mitochondrial health and combating age-related decline, leveraging its SS-31 mitochondria targeting peptide properties.
Neuromuscular Disorders
Studies are investigating the use of Elamipretide in conditions such as primary mitochondrial myopathy, aiming to improve muscle function and reduce disease symptoms.
Ophthalmic Diseases
The potential of Elamipretide for treating eye conditions like dry age-related macular degeneration (AMD) is being explored through rigorous clinical trials.
Cardiomyopathies
Elamipretide is being evaluated for its effectiveness in treating rare cardiomyopathies, such as Barth syndrome, by improving cardiac mitochondrial function.